Read by QxMD icon Read

Journal of Dermatological Treatment

Larisa Geskin, Daniel C Malone
PURPOSE: To conduct an exploratory cost-effectiveness analysis of systemic treatment options for more advanced cutaneous T-cell lymphoma (CTCL). METHODS: A cost-effectiveness model compared systemic bexarotene, denileukin diftitox, interferon alpha, methotrexate, pralatrexate, romidepsin, vorinostat, and extracorporeal photopheresis (ECP) treatment of CTCL. Treatment effectiveness data were extracted from published studies and/or US product labeling. Overall response, the primary effectiveness measure, was defined as the proportion of patients achieving complete or partial response...
December 1, 2017: Journal of Dermatological Treatment
Lian Liu, Gary Ong
BACKGROUND: Atopic dermatitis (AD) is a chronic, relapsing disease that requires maintenance treatment. This study examined the efficacy and safety of extended intermittent fluticasone propionate (FP) 0.05% cream, with emollient, vs emollient alone in children with AD. METHODS: Eligible patients (aged 1-17 years) received FP 0.05% cream twice daily for 4 weeks (acute phase) then randomized (1:1) to FP 0.05% cream once daily, twice per week plus emollient (Group A) or emollient alone (Group B) for up to 20 weeks (maintenance phase)...
November 22, 2017: Journal of Dermatological Treatment
Yunlei Pan, Lina Xu, Jianjun Qiao, Hong Fang
Ustekinumab is a human monoclonal IgG1 antibody targeting the p40 subunit shared by IL-12 and IL-23. We reviewed the published literature by searching from PubMed, EMBASE, Web of Science and to evaluate the efficacy and safety of ustekinumab in the treatment of AD. Ten studies including eight cases and two RCT, comprising 107 patients, were included in the systematic review. Analysis all studies, a total of 58 patients (54.2%) gained an effective treatment with little adverse events. Ustekinumab is a well-tolerated and safe treatment with no significant difference in effect from placebo in patients with AD...
November 22, 2017: Journal of Dermatological Treatment
Verena Isak, Joseph L Jorizzo
Dermatomyositis is an autoimmune disease affecting both skin and muscle. Steroids are the first line treatment. However, no consensus regarding dosing, length of treatment, tapering speed, or when to add which immunosuppressant in case of steroid resistance, has been reached, as randomized-controlled trials are scarce. Especially data on long-term treatment is lacking in order to decide on the most effective treatment for long-term remission. Empiric evidence suggests that with an initially aggressive treatment with oral steroids followed by a slow taper, during which disease activity is adequately controlled, patients can be off therapy within typically 24-48 months, and remain disease-free without medication for over 20 years...
November 22, 2017: Journal of Dermatological Treatment
Malika Haque, Daniel L Coury
OBJECTIVES: To evaluate the safety and efficacy of an East Indian sandalwood oil (EISO) product as a topical treatment for molluscum contagiosum. MATERIALS AND METHODS: Ten subjects ranging in age from 22 months to 29 years were recruited. Subjects were instructed to apply an EISO product to the lesions twice daily. Subjects were monitored every two to three weeks during the study and were questioned regarding local or systemic side effects. Assessment of response was recorded by counting lesions and documented by photographs...
November 22, 2017: Journal of Dermatological Treatment
Melody Maarouf, Ashley K Clark, Dylan E Lee, Vivian Y Shi
PURPOSE: Targeted, immune-modulating drugs are at the forefront of therapy for HS, and a comprehensive clinical trial registry is needed to facilitate data pooling and clinical efficacy comparison. MATERIALS AND METHODS: A systematic review of the database was searched for planned, in-progress, completed, or terminated trials investigating the effect of targeted biologic therapies for hidradenitis suppurativa (HS). When results of RCTs were not available, case reports or series were included...
November 10, 2017: Journal of Dermatological Treatment
Daniel J No, Megan S Inkeles, Mina Amin, Jashin J Wu
Drug survival measures the length of time until discontinuation of a drug. The length of time a patient remains on a biologic drug is impacted by several factors such as tolerability, side effects, safety profile and effectiveness. To evaluate the long-term drug survival, data of the most commonly prescribed biologic medications used in the treatment of psoriasis, a systematic review was conducted. A literature search using PubMed, the Cochrane Library and the Cumulative Index to Nursing and Allied Health Literature from January 1 2010 to October 28 2016 identified 3734 abstracts...
November 10, 2017: Journal of Dermatological Treatment
Nasrin Saki, Mohammad Darayesh, Alireza Heiran
INTRODUCTION: Melasma is a benign, acquired and chronic hypermelanosis. Topical hydroquinone (HQ) is a conventional choice to treat melasma. Tranexamic acid (TA) is a relatively new brightening agent that interferes with keratinocyte-melanocyte interactions. The aim of the present study was to compare the efficacy and safety of TA intradermal injections with HQ in treating melasma. MATERIALS AND METHODS: In this split-face controlled trial, 37 patients were randomized to receive three monthly sessions of TA intradermal injections either on the right or the left side of their face and topical HQ once a night for three months on the other side...
November 9, 2017: Journal of Dermatological Treatment
Ali Balevi, Pelin Üstüner, Sümeyye A Kakşi, Mustafa Özdemir
PURPOSE: In the previous studies, positive effect of sunlight on seborrheic dermatitis may well be explained by the direct influence of UV-light on the yeasts. Narrow-band ultraviolet-B phototherapy appears to be a very effective and safe treatment option for patients with severe seborrheic dermatitis. We aimed to investigate the efficacy of narrow-band ultraviolet-B phototherapy as an alternative treatment for pityriasis versicolor. MATERIAL AND METHODS: A total of 38 patients diagnosed with disseminated pityriasis versicolor having more than four relapsing episodes within 12 months were treated with narrow-band ultraviolet-B phototherapy given three times weekly...
November 9, 2017: Journal of Dermatological Treatment
Daniel J No, Mina Amin, Tina Bhutani, Jashin J Wu
PURPOSE: Interleukin (IL)-17 and IL-23 inhibitors are the newest biologic agents used in the management of moderate-to-severe psoriasis. Active comparator studies allow for direct comparison of different biologic agents. We sought to systematically investigate the efficacy of newer biologic agents compared to earlier biologics. MATERIALS AND METHODS: We conducted a literature search for randomized control trials that compared the efficacy of a biologic agent with an active comparator...
November 6, 2017: Journal of Dermatological Treatment
J A Krooks, A G Weatherall, P J Holland
Approximately half of all patients presenting to dermatologists exhibit signs and symptoms of psychiatric conditions that are either primary or secondary to cutaneous disease. Because patients typically resist psychiatric consult, dermatologists often are on the front line in evaluating and treating these patients. Accordingly, distinguishing the specific underlying or resulting psychiatric condition is essential for effective treatment. The etiology, epidemiology, clinical presentation, diagnosis, and first-line treatment of specific primary psychiatric causes of dermatologic conditions, including delusional infestation, Morgellons syndrome, olfactory reference syndrome, body dysmorphic disorder, excoriation disorder, trichotillomania, and dermatitis artefacta are discussed here, followed by a discussion of the recommended treatment approach with an overview of the different first-line therapies discussed in this review, specifically cognitive behavioral therapy, atypical antipsychotics, selective serotonin reuptake inhibitors, and tricyclic antidepressants...
November 5, 2017: Journal of Dermatological Treatment
G Carretero, L Puig, J M Carrascosa, L Ferrándiz, R Ruiz-Villaverde, P de la Cueva, I Belinchon, E Vilarrasa, R Del Rio, J L Sánchez-Carazo, A López-Ferrer, F Peral, S Armesto, N Eiris, J Mitxelena, J Vilar, M Ara, C Soria
The advances in psoriasis management currently allow achieving a good control of the disease. In particular, with the latest developed molecules, available evidence suggests that it is possible to pose an ambitious therapeutic goal, such as a Dermatology Life Quality Index 0/1, a Physician Global Assessment 0/1, or a Psoriasis Area and Severity Index 90/100 response. However, patients often fail to achieve the complete clearance of their cutaneous lesions or the improvement of disease factors that impair their quality of life...
November 3, 2017: Journal of Dermatological Treatment
Alvin Lim
The use of complementary and alternative medicines in Australia has grown significantly. Much of this growth is due to their ease of accessibility from online vendors, often marketed with claims that are not scientifically tested. Black salve is a topical escharotic compound containing the active component sanguinarine, derived from the bloodroot plant. It has been advertised as a natural treatment for skin cancer. This article reviews the current state of black salve as an alternative skin cancer treatment, discussing its distribution and regulation, and provides a summary of clinical and laboratory studies...
November 3, 2017: Journal of Dermatological Treatment
Eun Jin Doh, Jiwon Kim, Dong Hun Lee, Je-Young Park
BACKGROUND: A multimodal approach is essential for neck rejuvenation because many factors contribute to the aging of the neck. OBJECTIVES: We evaluated the effect of combined therapy using microfocused ultrasound with visualization (MFU-V), neuromodulator injection, and filler injection for neck rejuvenation. METHODS: Subjects were sequentially treated with three kinds of interventions in a single session as follows: (A) MFU-V or calcium hydroxyapatite injection for restoring skin laxity; (B) hyaluronic acid filler injection for horizontal neck lines; and (C) neuromodulator injection for platysmal bands...
November 3, 2017: Journal of Dermatological Treatment
K L Hon, M Ip, C K Wong, Ben C L Chan, P C Leung, T F Leung
BACKGROUND: In a series of bench and clinical trials, our group has determined the immunologic effects and clinical efficacy of a concoction of five herbal ingredients (PentaHerbs Formula, PHF) in treating children with atopic eczema (AE). This study investigates the antimicrobial effects that may be induced with PHF treatment. METHODS: We investigated the effects of PHF on the minimal inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of staphylococcus aureus and various bacteria that are commonly present on the skin of patients with AE...
November 3, 2017: Journal of Dermatological Treatment
Johannes Baur, Katrin Mathe, Anja Gesierich, Gerhard Weyandt, Armin Wiegering, Christoph-Thomas Germer, Jörg O W Pelz
Introdurction: Current guidelines for malignant melanoma do not set a concrete cut-off limit for the number of lymph nodes to be resected during regional lymph node dissection (LND). Here we investigate if extended LND (ext-LND) has an impact on surgical morbidity and oncological outcome in melanoma patients. MATERIAL AND METHODS: 245 melanoma patients receiving axillary or inguinal LND in curative intention were investigated retrospectively. Ext-LND was defined as axillary LND with 20 or more and inguinal LND with 10 or more resected lymph nodes...
November 3, 2017: Journal of Dermatological Treatment
Pingjiao Chen, Changxing Li, Rujun Xue, Huiheng Chen, Xin Tian, Kang Zeng, Xibao Zhang, Jingyao Liang
BACKGROUND: There is a few evidence-based information regarding the efficacy and safety of acitretin treatment in children with pustular psoriasis (PP). OBJECTIVE: This study aimed to provide an additional evidence for this field. METHODS: A retrospective study was undertaken for 15 children with PP, received acitretin in doses of 0.6-1.0 mg/kg/day for 4-6 weeks, the transition dose in 0.2-0.4mg/kg/day for 4-6 weeks and maintenance dose of 0...
November 3, 2017: Journal of Dermatological Treatment
Nupur U Patel, Alexandra Grammenos, Asha Gowda, Omobola Onikoyi, Steven R Feldman
The safety and potential side effects of desoximetasone 0.25% and 0.05% sprays have not previously been studied. The primary objective of this study was to determine the irritation potential of desoximetasone 0.25%, 0.05%, and vehicle sprays in response to irradiation. 34 subjects were enrolled in the study, each with 3 study treatments (desoximetasone 0.25%, 0.05% topical sprays, and vehicle) were applied to 2 sites each on the back of every subject, with half of the sites irradiated with filtered UV light...
November 3, 2017: Journal of Dermatological Treatment
Nupur U Patel, Asha Gowda, Alexandra Grammenos, Omobola Onikoyi, Steven R Feldman
PURPOSE: Desoximetasone 0.25% topical spray is a novel formulation that has not been tested or approved for safety and efficacy. The primary objective was to determine the potential of desoximetasone 0.25% and 0.05% topical sprays, as well as vehicle to induce a photoallergic skin reaction after repeated topical application and irradiation to the skin using a controlled photopatch testing procedure. MATERIALS/METHODS: 53 subjects completed the study, each with 6 application sites (2 of each treatment), 3 of which were irradiated and 3 non-irradiated, for an induction period of 3 weeks and then challenge period at week 6...
November 3, 2017: Journal of Dermatological Treatment
Kevin Veverka, Steven R Feldman
PURPOSE: IL-17 antagonists are effective for psoriasis in clinical trials, but long-term safety is not fully characterized. Since chronic mucocutaneous candidiasis (CMC) is caused by defects in the IL-17 pathway, CMC risk data has been touted as providing reassurance about the safety of IL-17 antagonism. METHODS: We performed a literature review to identify patients with CMC and compared the prevalence of cancer in these patients to the reported 5-year prevalence...
October 27, 2017: Journal of Dermatological Treatment
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"